메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Jeonghoon Ha (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital)
저널정보
대한골대사학회 대한골대사학회지 Journal of Bone Metabolism Vol.31 No.3
발행연도
2024.8
수록면
246 - 249 (4page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Osteoporosis, characterized by diminished bone density and microarchitectural deterioration, has become a global health concern and can lead to increased fracture susceptibility and subsequent morbidity and mortality.[1] The goal of treating postmenopausal osteoporosis is to increase bone density and prevent fractures, and various medications have been developed to achieve these goals.[2,3] Denosumab, a fully human monoclonal antibody targeting receptor activator of nuclear factor-κB ligand (RANKL), has emerged as a key therapeutic tool for osteoporosis management.[4] Denosumab is a RANKL-mediated osteoclast differentiation inhibitor that strongly inhibits bone resorption, thereby reducing bone loss and lowering fracture incidence, making it a potent treatment for patients at high risk of fractures.[4,5] Many clinical trials and real-world studies have demonstrated denosumab’s efficacy in improving bone mineral density (BMD) and mitigating fracture risk.[5,6] Therefore, denosumab is widely accepted by clinicians as an important treatment for osteoporosis management, as reflected in clinical guidelines.[2,7-11] Long-term studies of up to 10 years have demonstrated the continued effectiveness of denosumab in increasing bone density and preventing fractures.[5,12] Moreover, continuing treatment beyond the initial years confers further fracture risk mitigation, highlighting denosumab's sustained efficacy over prolonged durations.[5] Notably, a 10-year denosumab treatment yielded a substantial increase in spine (21.7%) and hip BMD (9.2%).[5] Denosumab’s potent inhibitory effect on bone resorption effectively reduces fracture risk and increases the likelihood of reaching target BMD compared to bisphosphonates.[13] Therefore, once fracture risk has been reduced to moderate after a period of denosumab treatment, the drug can be discontinued in favor of sequential treatment with bisphosphonates.[2] However, in some clinical situations, once denosumab treatment has been initiated, it may need to be continued. Some patients who have reached their goals wish to continue denosumab treatment because of high adherence, dosing convenience, and fewer side effects. [14] In patients who remain at high risk of fracture after 10 years of treatment, continued treatment should be considered.[7] Denosumab discontinuation results in a rebound phenomenon and should be followed by an agent such as bisphosphonate. [15,16] However, in patients with advanced renal dysfunction, sequential therapy with bisphosphonates is not feasible, and there are difficult clinical situations where, once denosumab is administered, long-term therapy should be considered. Denosumab was first administered to patients in South Korea in November 2016. Some patients will require longterm denosumab treatment (>10 years). However, there are currently no reports on the effect of denosumab treatment on BMD after a 10-year administration. Therefore, we used a statistical approach to predict the changes in BMD after 10 years of denosumab treatment. In this study, we analyzed the results of the original Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension study and clinical studies to make statistical projections of the effects of denosumab treatment after 10 years. Utilizing multiscale indirect response models based on pharmacological studies is an appropriate approach to understanding the integrated dynamic impact of denosumab on longitudinal changes in BMD. [17-19] We utilized the following two methods as predictive models.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청
참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0